Alto Neuroscience vs MasterControl
Side-by-side comparison of AI visibility scores, market position, and capabilities
Nasdaq-listed (ANRO). Raised $120M PIPE (2026) to fund ALTO-207 Phase 2b. FDA Fast Track for ALTO-101. Biomarker-stratified psychiatry matching patients to drugs using brain biology. 4 data readouts through 2027.
About
Alto Neuroscience is a publicly-listed (Nasdaq: ANRO) clinical-stage biotech applying biomarker-stratified patient selection to psychiatry — matching patients to drugs based on brain biology rather than symptom checklists that have historically produced inconsistent treatment outcomes. The company raised a $120 million PIPE in 2026 to fund Phase 2b development of ALTO-207, a fixed-dose combination of pramipexole and ondansetron for treatment-resistant depression (TRD). The FDA has granted Fast Track designation for ALTO-101, and Alto has four clinical data readouts expected through 2027.
MasterControl is the leading QMS and MES platform for regulated life sciences industries, serving 1,100+ companies with $200M revenue in 2025; valued at $1.3B after $150M from Sixth Street, acquired Qualer in Mar 2025.
About
MasterControl is a leading provider of quality management system (QMS) and manufacturing execution system (MES) software for regulated industries, with a primary focus on pharmaceuticals, medical devices, biotechnology, and food and beverage. The company's AI-powered platform digitizes and automates compliance-critical workflows including document control, training management, audit management, change control, corrective and preventive action (CAPA), risk management, and electronic batch records — replacing paper-based processes that are error-prone, audit-vulnerable, and incompatible with modern manufacturing velocity.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.